Kimball Electronics, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2023, compared with fiscal 2022. Although the request metadata says “2022 Q4,” this filing is an annual report for fiscal 2023; it does not provide a clear standalone fourth-quarter financial summary.
Business context
Kimball Electronics provides contract electronics manufacturing, engineering, and supply-chain services, along with manufacturing of medical devices and disposables, precision molded plastics, and automation and inspection equipment. Its end markets are automotive, medical, and industrial. The company reports one aggregated segment and operates manufacturing facilities across the United States, China, Mexico, Poland, Romania, Thailand, and Vietnam.
Financial results and liquidity
| Metric | FY2023 | FY2022 | Change or context |
|---|---|---|---|
| Net sales | $1,823.4 million | $1,349.5 million | Up 35%; foreign exchange reduced growth by 3% |
| Gross profit / margin | $156.2 million / 8.6% | $104.6 million / 7.8% | Margin improved 0.8 percentage points |
| Operating income / margin | $87.7 million / 4.8% | $52.5 million / 3.9% | Operating income up 67% |
| Net income | $55.8 million | $31.3 million | Up 79% |
| Diluted earnings per share | $2.22 | $1.24 | Up 79% |
| Operating cash flow | $(13.8) million | $(83.2) million | Cash use narrowed, chiefly due to working-capital movements |
| Capital expenditures | $90.7 million | $74.7 million | Primarily facility expansions and new business awards |
| Cash and cash equivalents | $43.0 million | $49.9 million | At June 30 |
| Borrowings under credit facilities | $281.5 million | $180.6 million | Increased $100.9 million year over year |
Automotive sales rose 41% to $820.1 million, medical sales rose 26% to $494.0 million, and industrial sales rose 33% to $474.6 million. Automotive represented 45% of sales, medical 27%, and industrial 26%. Nexteer Automotive, Philips, and ZF accounted for 15%, 14%, and 12% of sales, respectively.
Working capital was $454.3 million, the current ratio was 2.0, and the debt-to-equity ratio was 0.5 at fiscal year-end. Management reported $149.1 million of short-term liquidity, comprising cash and available credit, and stated that available resources should meet operating and working-capital needs for at least 12 months. The company was in compliance with its credit-facility covenants.
Material changes and unusual items
- Revenue and profit increased substantially, supported by stronger demand, improved component availability, and new program launches and ramp-ups. Gross margin benefited from higher-volume leverage and favorable product mix.
- Operating cash flow remained negative. Receivables growth used $82.4 million of cash and inventory growth used $50.2 million; strategic inventory purchases supported expansions and helped mitigate component shortages.
- Interest expense rose to $16.3 million from $2.7 million, reflecting higher borrowing and interest rates. The weighted-average rate on outstanding credit-facility borrowings was 6.8%, versus 2.7% a year earlier.
- A change in estimated useful lives for surface-mount production equipment reduced FY2023 depreciation expense by $6.8 million and increased net income by $5.3 million, or $0.21 per diluted share. This was a significant estimate affecting year-over-year earnings comparability.
- Accounts receivable sold without recourse under factoring arrangements increased to $485.4 million from $303.4 million; related fees rose to $4.8 million from $1.6 million.
- Open orders fell 33% to $798 million. Management attributed the decline to shorter order lead times and better component availability, and cautioned that open orders may not indicate future sales.
Outlook, commentary, and risks
Management expects working capital and inventory levels to normalize as component shortages abate and expanded facilities ramp production. It anticipates continued investment in capacity and capabilities; capital expenditure commitments were approximately $13 million at year-end. No specific consolidated revenue or earnings guidance for fiscal 2024 is provided in the supplied filing text.
Management expects fiscal 2024 medical sales to be affected by lower sales to a large medical customer remediating a recall; the filing says the recall’s cause is unrelated to products supplied by Kimball Electronics. Management also said inflation in components, labor, freight, and other operating costs had pressured profitability, while customer pricing arrangements had mitigated a majority of those increases; the future financial impact of supply-chain constraints was not reasonably estimable and could be material.
- Customer concentration and short-term ordering: three customers generated 41% of FY2023 sales, and customers generally do not commit to production schedules beyond a quarter.
- Supply-chain availability, cost inflation, tariffs, and shipping delays may disrupt production or raise costs.
- International operations expose the company to currency, geopolitical, regulatory, tax, and cash-repatriation risks. Foreign operations held $41.4 million of cash; approximately $420 million of foreign subsidiary earnings were reported as unremitted and intended to remain invested abroad.
- Higher floating interest rates and increased debt may pressure earnings and liquidity. The $50 million secondary revolving facility matures February 2, 2024.
- Goodwill at the GES reporting unit had fair value less than 2% above carrying value in the FY2023 impairment test; adverse market changes could lead to a potentially material impairment.
- The auditor identified revenue recognition for contracts recognized over time as a critical audit matter because estimating anticipated margins requires judgment. Contract assets were $78.8 million at year-end.
- The filing reports no pending legal proceedings beyond routine matters expected not to have a material adverse impact. Management and the auditor concluded internal control over financial reporting was effective.
Important facts for investors to verify
- Whether working capital, inventory, and operating cash flow improve as shortages ease and facility expansions reach production scale.
- Whether the reported earnings benefit from longer equipment useful lives is appropriately considered when assessing underlying profitability.
- How the medical customer recall affects fiscal 2024 sales, and whether the company can replace expiring programs and sustain customer demand.
- Debt balances, borrowing costs, covenant headroom, and the refinancing or repayment plan for the secondary facility maturing in February 2024.
- Whether the GES reporting unit’s narrow impairment cushion and revenue-recognition margin estimates change in future periods.